AHC
AKBA icon

Adell Harriman & Carpenter’s Akebia Therapeutics AKBA Stock Holding History

Adell Harriman & Carpenter’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-21,037
Closed -$102K – 140
2019
Q2 		$102K Hold
21,037
– – 0.02% 133
2019
Q1 		$172K Hold
21,037
– – 0.03% 139
2018
Q4 		$116K Buy
+21,037
New +$165K 0.03% 144

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adell Harriman & Carpenter's AKBA Position: Q3 2019 in Review

Adell Harriman & Carpenter sold out of Akebia Therapeutics (AKBA) in Q3 2019, closing a stake of 21,037 shares — an estimated $102K sold.

Adell Harriman & Carpenter first reported a position in AKBA in Q4 2018 and held it in 3 quarters. The position peaked at $172K in Q1 2019. 150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • Adell Harriman & Carpenter reported no remaining Akebia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Adell Harriman & Carpenter sold 21,037 Akebia Therapeutics shares in Q3 2019, an estimated $102K.
  • Adell Harriman & Carpenter first reported a position in Akebia Therapeutics in Q4 2018 and held it in 3 quarters.
  • Adell Harriman & Carpenter's Akebia Therapeutics position peaked at $172K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on Adell Harriman & Carpenter's 13F filing for Q3 2019, filed 8 Nov 2019.